Janetschek G, Jeschke S, Leeb K, Prammer P, Ziegerhofer J, Sega W
Dept. of Urology, Servicio de Urología, Elisabethinen Hospital, Linz, Austria.
Actas Urol Esp. 2007 Jun;31(6):686-92. doi: 10.1016/s0210-4806(07)73706-3.
Proper assessment of lymph node status is of crucial importance in the management of newly diagnosed prostate cancer. Early stage metastatic disease takes the form of microscopic tumor-cell deposits rather than grossly enlarged nodes. So far there is no imaging technique, however, which allows detecting small metastases in the range of a few millimetres. Therefore pelvic lymph node dissection (PLND) is the only reliable method of staging for clinically localized prostate cancer. The cornerstone of radioguided prostate surgery is a radiopharmaceutical--a carrier molecule labeled by radionuclide. After injection to at the prostate, the radiopharmaceutical crosses the lymphatic pores and migrates into the lymph vessels and from there to the first echelon of lymph nodes. We were the first to show that sentinel PLND can be performed by means of laparoscopy preceding laparoscopic radical prostatectomy. Our most recent publication presents data of 140 patients with clinically localized prostate cancer in which laparoscopic sentinel PLND was performed preceding radical prostatectomy from November 2001 to January 2005. On the preoperative scintigraphy SLNs were detected bilaterally,unilaterally, not on the pelvic-walls in 113 (80.7%), 20 (14.2%) and 6 (4.2%) patients and intraoperatively in 96 (68.6%), 36 (25.7%), 8 (5.7%) patients respectively. In 99 out of 140 patients (70.7%) intraoperatively SLN was detected in the same position as on preoperative scan. At least one SLN was detected in 133 patients (95.3%). Whenever PLND is indicated it should not be limited to lymph node sampling as provided by standard limited PLND but has to be performed in the template of extended PLND. There is only limited experience with sentinel PLND, but all the data collected so far indicate that this method has the potential to become an alternative to extended PLND since it allows for reduction of the extent of PLND without compromising diagnostic accuracy.
准确评估淋巴结状态在新诊断前列腺癌的治疗中至关重要。早期转移性疾病表现为微小肿瘤细胞沉积,而非淋巴结明显肿大。然而,目前尚无成像技术能够检测出几毫米大小的微小转移灶。因此,盆腔淋巴结清扫术(PLND)是临床局限性前列腺癌唯一可靠的分期方法。放射性引导前列腺手术的关键是一种放射性药物——一种由放射性核素标记的载体分子。将放射性药物注射到前列腺后,它会穿过淋巴孔,迁移到淋巴管,然后到达第一级淋巴结。我们是首个表明可在腹腔镜根治性前列腺切除术之前通过腹腔镜进行前哨淋巴结PLND的研究团队。我们最近的一篇论文展示了140例临床局限性前列腺癌患者的数据,这些患者在2001年11月至2005年1月期间接受了腹腔镜根治性前列腺切除术,术前均先进行了腹腔镜前哨淋巴结PLND。术前闪烁显像显示,双侧、单侧、未在盆腔壁发现前哨淋巴结的患者分别有113例(80.7%)、20例(14.2%)和6例(4.2%),术中发现前哨淋巴结的患者分别有96例(68.6%)、36例(25.7%)和8例(5.7%)。140例患者中有99例(70.7%)术中发现的前哨淋巴结位置与术前扫描一致。133例患者(95.3%)至少检测到一个前哨淋巴结。只要有指征进行PLND,就不应局限于标准有限PLND所提供的淋巴结采样,而必须在扩大PLND的模板范围内进行。前哨淋巴结PLND的经验有限,但目前收集到的所有数据表明,该方法有可能成为扩大PLND的替代方法,因为它在不影响诊断准确性的前提下,可以减少PLND的范围。